Nov. 12, 2020 Updated

A Therapeutic Option for Glioblastoma using pH-Sensitive Nanomicelles

Kawasaki Institute of Industrial Promotion Innovation Center of NanoMedicine (Director General: Dr. Kazunori Kataoka, Location: Kawasaki-ku, Kawasaki City, Abbreviation: iCONM) demonstrated a Therapeutic Option for Glioblastoma using pH-Sensitive Nanomicelles in a collaboration study with the Department of Bioengineering, Graduate School of Engineering, The University of Tokyo. The contents of this research were published in Biomaterials.

At the press seminar held online on Thursday, November 12, Dr. Kazunori Kataoka, Director General, Innovation Center of NanoMedicine, Dr. Sabina Quader, Senior Research Scientist, Kataoka/Kinoh Lab., Innovation Center of NanoMedicine, and others took the rostrum, and there were the deep, enthusiastic and passionate discussions with journalists in science section, the general paper and biotech journals.